Navigation Links
InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
Date:9/14/2009

LOS ALTOS, Calif., Sept. 14 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Linda Slanec Higgins, PhD has been named Chief Operating Officer. Since late 2007, Dr. Higgins has served as InteKrin's Chief Scientific Officer after joining the Company earlier that year. Over the past two years, Dr. Higgins has had increasingly broad operational and strategic responsibility in key areas including CMC and dosage form development, Regulatory Affairs, Corporate Development and Product Development.

"Linda's contributions to InteKrin's progress have been extraordinarily impactful and decisive," said Denny Lanfear, InteKrin Chief Executive. "By large measure, her leadership and capabilities have allowed us to move INT131 forward in many dimensions over the past two plus years and successfully surmount the considerable challenges confronting privately funded development stage companies."

"I am very pleased to have contributed to the advancement of this important therapeutic," said Dr. Higgins. "We at InteKrin look forward to completing our Phase 2b efforts and moving on into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
2. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces $20 Million Series C Financing
4. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
5. Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials With AT-406
6. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
7. Oxygen Biotherapeutics, Inc. Posts Latest Blog by CEO Chris Stern
8. Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference
9. New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary, Helsinn Therapeutics (U.S.) Inc.
10. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
11. Reportlinker Adds Autoimmune Disease Therapeutics Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/12/2016)... ... 12, 2016 , ... According to an article published February 4th ... significant portion of hernia repairs throughout the United States. Commenting on this article, Beverly ... that this trend has not only been expected, but it seems to be a ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner Tal Rabinowitz ... no time to decompress, Rabinowitz found herself drawn to a casual meditation class while ... on her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into Cielo®, ... to offer real-time business intelligence (BI) to their small and medium business (SMB) ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... , Ungarn, February 12, 2016 ... das sich auf den ungedeckten medizinischen Bedarf ... positive Ergebnisse seines klinischen Forschungsprogramms bekannt. Das ... beschäftigt, ergab Verbesserungen ihrer respiratorischen Funktionen und ... ltd , ein Medizintechnikunternehmen, das sich auf ...
Breaking Medicine Technology: